PROLOR Biotech, Inc. (Prolor) is a development-stage biopharmaceutical company, utilizing technology to develop longer-acting, versions of therapeutic proteins. The Company is using the carboxyl terminal peptide (CTP) technology to develop new versions of certain therapeutic proteins. As of December 31, 2011, the Company�s product development program is focused on extending the life span of Human Growth Hormone (hGH), Factor IX, Anti-Obesity Peptide Oxyntomodulin, Factor VIIa, Interferon B and Erythropoietin (EPO) and Atherosclerosis and rheumatoid arthritis long-acting therapies. In August 2011, the Company has reported positive results from a Phase I study of its longer-acting version of hGH, referred to as hGH-CTP. In February 2012, the Company completed the study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.